

Yuan Qi  
Scientific editor  
World Journal of Diabetes

25<sup>th</sup> September 2015

Dear Professor Qi,

**Re: Manuscript Number 19786**  
**Irwin & Flatt "New perspectives on exploitation of incretin peptides for the treatment of diabetes and related disorders"**

Thank-you for the email on 17<sup>th</sup> September 2015 with editorial evaluation of the above review article for publication in *World Journal of Diabetes*.

We are pleased to note that you found our manuscript to be of interest and that the article is recommended for publication after appropriate revision. We have enclosed detailed comments in reply to each of the points raised by the two Reviewers, together with the corresponding details of changes made to the manuscript.

We hope that you will consider the revised version of our paper acceptable for publication in *World Journal of Diabetes*. We believe that it will make a timely, interesting and stimulating article for the readers.

We look forward to hearing the outcome of your review of this revised manuscript in due course.

Yours Sincerely,

Dr. Nigel Irwin

School of Pharmacy and Pharmaceutical Sciences  
University of Ulster  
Coleraine  
N. Ireland,  
BT52 1SA, UK

Email: n.irwin@ulster.ac.uk  
Tel: ++44 (0) 28 70124574  
Fax: ++44 (0) 28 70123939

**Manuscript Number 19786 ‘New perspectives on exploitation of incretin peptides for the treatment of diabetes and related disorders’**

**Reviewer 1:**

We thank the Reviewer for his/her valued appraisal of our manuscript. We appreciate his/her comments in particular with respect to their remark that: *‘This is an interesting, well written review addressing a topical issue’*.

The Reviewer has made one suggestion, he/she states: *‘I’d only suggest the authors to add a Table including an up-to-date revision of drugs acting on incretin system already available or in clinical trials and a schematic figure showing the main downstream effects of receptor activation of these peptides. This improvement would be helpful to better understand this matter’*. We thank the Reviewer for this comment, and are happy to comply with the request. We have now inserted a Table (Table 1) that includes full details of all current EMA approved incretin-based drugs. This Table has been cited appropriately within the text. In addition, the authors have devised a scheme that illustrates the major signalling pathways involved in the insulinotropic effects of GIP, GLP-1, glucagon and CCK in pancreatic beta-cells. This Figure (Figure 1) has been cited appropriately within the text. We thank the Reviewers for these suggestions, and agree with that these changes are *‘helpful to better understand this matter’*.

**Reviewer 2:**

We thank the Reviewer for his/her evaluation of our manuscript. In particular, his/her comments that *‘Dr Irwin and Flatt provide a very thorough, readable, well organized and up to date account of the incretin peptides and their derived pharmaceuticals in this article’*. We are also pleased to note that he/she considers that the manuscript is *‘well worth publication’* and has made no further suggestions for improvement.

**Steps for revision**


The authors have completed the following recommended steps for revision of articles in World Journal of Diabetes:

**Step 1.** Our manuscript has been suitably revised according to the Reviewers comments.

**Step 2.** The manuscript has been updated according to the Guidelines and Requirements for Manuscript Revision-Review.

**Step 3.** The authors have provided an audio file of the final core tip of the manuscript

**Step 4.** The authors are not members of CrossRef.org, and do not have available funds to apply for membership. As such, the manuscript has not been subjected to CrossCheck analysis. However, we are more than happy for our manuscript to undergo CrossCheck analysis by the World Journal of Diabetes on our behalf. The final title has been searched on Google Scholar search, and a screenshot image of the result is shown below:



**Step 5.** As requested, we have provided a ‘Duality of Interest’ statement within the revised manuscript.

**Step 6.** Our manuscript does not require English language editing. As noted by both Reviewers, the language of the manuscript is already of ‘Grade A’ standard.

**Step 7.** The Copyright Assignment form has been signed and included with the revision as a scanned PDF.

**Step 8.** The revised manuscript will be submitted as requested.